PMC:7696151 / 44578-44943 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1247","span":{"begin":59,"end":67},"obj":"Species"},{"id":"1248","span":{"begin":268,"end":276},"obj":"Species"},{"id":"1253","span":{"begin":79,"end":92},"obj":"Chemical"},{"id":"1254","span":{"begin":97,"end":100},"obj":"Chemical"},{"id":"1255","span":{"begin":124,"end":127},"obj":"Chemical"},{"id":"1256","span":{"begin":204,"end":217},"obj":"Chemical"},{"id":"1257","span":{"begin":290,"end":293},"obj":"Chemical"}],"attributes":[{"id":"A1247","pred":"tao:has_database_id","subj":"1247","obj":"Tax:9606"},{"id":"A1248","pred":"tao:has_database_id","subj":"1248","obj":"Tax:9606"},{"id":"A1253","pred":"tao:has_database_id","subj":"1253","obj":"MESH:D012460"},{"id":"A1254","pred":"tao:has_database_id","subj":"1254","obj":"MESH:D006886"},{"id":"A1255","pred":"tao:has_database_id","subj":"1255","obj":"MESH:D006886"},{"id":"A1256","pred":"tao:has_database_id","subj":"1256","obj":"MESH:D012460"},{"id":"A1257","pred":"tao:has_database_id","subj":"1257","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" comparative double-blind, randomized trials, involving 60 patients each, with sulfasalazine and HCQ have demonstrated that HCQ showed no significant differences among overall clinical effects respect to sulfasalazine, but presented a later onset. In the first study, patients treated with HCQ (400 mg/day for 6 months and 200 mg/day for the next 6 months) experien"}